Article PDF
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
During the past three years, the author has received payments for consulting on spirometry quality assurance programs for phase III clinical trials from Pfizer (varenicline for smoking cessation in patients with COPD) and InterMune (for patients with idiopathic pulmonary fibrosis). He has received no consulting or travel expense reimbursement from any companies which make pulmonary function equipment or spirometers.
Rights and permissions
About this article
Cite this article
Enright, P. Don't prescribe tiotropium for smokers with an FEV1 above 60% predicted. Prim Care Respir J 18, 119–120 (2009). https://doi.org/10.3132/pcrj.2009.00014
Received:
Published:
Issue Date:
DOI: https://doi.org/10.3132/pcrj.2009.00014